Screener / SEC EDGAR /CIK 0000818479 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Dental Equipment & Supplies

DENTSPLY SIRONA Inc. XRAY

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 0 above the last range given
Within the range 1 of 2 range targets
Below the range 1 below the last range given

The numbers XRAY said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Diluted EPS (company-defined)
Fiscal 2026
Given $1.40 to $1.50 release Feb 26, 2026
Kept $1.40 to $1.50 release May 5, 2026
Lowered $1.20 to $1.30 release Nov 5, 2026
– No standard number
The company's words
FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50 (1) release Feb 26, 2026
The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50. release May 5, 2026
Updated FY2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30 release Nov 5, 2026
Revenue
Fiscal 2026
Given $3.50B to $3.60B release Feb 26, 2026
Kept $3.50B to $3.60B release May 5, 2026
– Not reported yet
The company's words
FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50 (1) release Feb 26, 2026
The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50. release May 5, 2026
Diluted EPS (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $1.80 to $2.00 release Feb 27, 2025
Kept $1.80 to $2.00 release May 8, 2025
Kept $1.80 to $2.00 release Aug 7, 2025
Lowered $1.60 release Nov 6, 2025
– No standard number
The company's words
FY25 outlook: net sales in the range of $3.50 billion to $3.60 billion with organic sales down (4.0%) to (2.0%); adjusted EPS of $1.80 to $2.00 (1) release Feb 27, 2025
The Company is maintaining its 2025 outlook for organic sales in the range of down (4.0%) to (2.0%), and adjusted EPS in the range of $1.80 to $2.00. release May 8, 2025
The Company is maintaining its 2025 outlook for net sales of $3.60 billion to $3.70 billion, down (4.0%) to (2.0%) on a constant currency basis, and adjusted EPS in the range of $1.80 to $2.00. release Aug 7, 2025
Updated 2025 Outlook … Adjusted EPS is expected to be approximately $1.60. release Nov 6, 2025
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $3.50B to $3.60B release Feb 27, 2025
Raised $3.60B to $3.70B release Aug 7, 2025
$3.68B
10-K filed 2026-02-26
Within the range
The company's words
FY25 outlook: net sales in the range of $3.50 billion to $3.60 billion with organic sales down (4.0%) to (2.0%); adjusted EPS of $1.80 to $2.00 (1) release Feb 27, 2025
The Company is maintaining its 2025 outlook for net sales of $3.60 billion to $3.70 billion, down (4.0%) to (2.0%) on a constant currency basis, and adjusted EPS in the range of $1.80 to $2.00. release Aug 7, 2025
Diluted EPS (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $2.00 to $2.10 release Feb 29, 2024
Kept $2.00 to $2.10 release May 2, 2024
Lowered $1.96 to $2.02 release Jul 31, 2024
Lowered $1.82 to $1.86 release Nov 7, 2024
– No standard number
The company's words
FY24 outlook: organic sales flat to up 1.5%; adjusted EPS of $2.00 to $2.10 release Feb 29, 2024
The Company is maintaining its 2024 outlook for organic sales growth in the range of flat to up 1.5%, and adjusted EPS in the range of $2.00 to $2.10. release May 2, 2024
Revised FY24 outlook: organic sales down (1%) to flat (previously flat to up 1.5%); adjusted EPS of $1.96 to $2.02 (previously $2.00 to $2.10) release Jul 31, 2024
Revised FY24 outlook: expect organic sales of (3.5%) to (2.5%) (previously (1%) to flat); adjusted EPS of $1.82 to $1.86 (previously $1.96 to $2.02) release Nov 7, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $3.96B to $4.02B release Feb 29, 2024
$3.79B
10-K filed 2025-02-27
Below the range
The company's words
The 2024 outlook includes anticipated net sales in the range of $3.96 billion to $4.02 billion, flat to up 1.5% on an organic basis. release Feb 29, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (14 releases since 2024-01-09), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/XRAY/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.